Ori Gutwerg Sells 2,772 Shares of ANI Pharmaceuticals (NASDAQ:ANIP) Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) SVP Ori Gutwerg sold 2,772 shares of the stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $79.50, for a total value of $220,374.00. Following the completion of the sale, the senior vice president owned 78,696 shares of the company’s stock, valued at $6,256,332. The trade was a 3.40% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Ori Gutwerg also recently made the following trade(s):

• On Tuesday, March 3rd, Ori Gutwerg sold 2,060 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $76.50, for a total value of $157,590.00.

ANI Pharmaceuticals Stock Up 1.7%

NASDAQ ANIP traded up $1.38 during trading on Wednesday, reaching $80.88. 308,836 shares of the company’s stock were exchanged, compared to its average volume of 412,504. The company has a current ratio of 3.12, a quick ratio of 2.52 and a debt-to-equity ratio of 1.06. ANI Pharmaceuticals, Inc. has a fifty-two week low of $56.71 and a fifty-two week high of $99.50. The company’s fifty day simple moving average is $77.08 and its 200-day simple moving average is $80.70. The firm has a market capitalization of $1.81 billion, a PE ratio of 20.48 and a beta of 0.46.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share for the quarter, beating the consensus estimate of $1.28 by $0.77. ANI Pharmaceuticals had a return on equity of 27.51% and a net margin of 9.98%.The company had revenue of $237.46 million for the quarter, compared to analysts’ expectations of $207.63 million. During the same quarter in the previous year, the business posted $1.70 EPS. The business’s revenue for the quarter was up 20.5% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Sell-side analysts predict that ANI Pharmaceuticals, Inc. will post 7.73 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have weighed in on ANIP shares. Guggenheim lifted their target price on ANI Pharmaceuticals from $115.00 to $124.00 and gave the company a “buy” rating in a research note on Friday, January 16th. Wall Street Zen raised ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Finally, Zacks Research upgraded ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Wednesday, April 15th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, ANI Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $107.33.

Institutional Trading of ANI Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the company. Divisadero Street Capital Management LP purchased a new stake in shares of ANI Pharmaceuticals during the third quarter worth $21,454,000. Campbell & CO Investment Adviser LLC purchased a new stake in shares of ANI Pharmaceuticals during the third quarter worth $1,597,000. Apis Capital Advisors LLC raised its holdings in shares of ANI Pharmaceuticals by 28.1% during the third quarter. Apis Capital Advisors LLC now owns 164,000 shares of the specialty pharmaceutical company’s stock worth $15,022,000 after acquiring an additional 36,000 shares in the last quarter. Decker Retirement Planning Inc. raised its holdings in shares of ANI Pharmaceuticals by 76,862.5% during the third quarter. Decker Retirement Planning Inc. now owns 36,942 shares of the specialty pharmaceutical company’s stock worth $3,384,000 after acquiring an additional 36,894 shares in the last quarter. Finally, SG Americas Securities LLC increased its position in ANI Pharmaceuticals by 791.1% during the third quarter. SG Americas Securities LLC now owns 22,847 shares of the specialty pharmaceutical company’s stock worth $2,093,000 after buying an additional 20,283 shares during the last quarter. 76.05% of the stock is currently owned by hedge funds and other institutional investors.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.